NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06441331 2025-12-17
KinLET
ITM Solucin GmbH
Phase 1 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05387603 2025-09-10
START-NET
Lund University Hospital
Phase 3 Recruiting
NCT03049189 2025-05-30
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT04997317 2025-04-13
PROMENADE
University Hospital, Basel, Switzerland
Phase 1/2 Recruiting
NCT06045260 2024-08-13
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT05359146 2024-04-19
Beta plus
University Hospital, Basel, Switzerland
Phase EARLY_PHASE1 Recruiting
NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT04790708 2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA Unknown
NCT04194125 2020-11-04
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
University of Warmia and Mazury
Phase 2 Unknown